Hypertension and insulin resistance Circulatory System Hypertension
Conditions
Interventions
A randomised double-blind control crossover design will be employed. All antihypertensive agents will be withdrawn and placebo substituted for six weeks. During this period blood pressure will be moni
Sponsors
Belfast Health and Social Care Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged under 70 years, either sex 2. Mild essential hypertension
Exclusion criteria
Exclusion criteria: 1. Presence of diabetes mellitus 2. Significant obesity (body mass index [BMI] exceeding 35 kg/m^2) 3. Cardiac, renal or hepatic disease 4. A history of gout 5. Any treatment that may affect insulin action 6. Hyperkalaemia 7. Taking potassium sparing diuretics, potassium supplements or strong inhibitors of CYP 34A 8. Women who are pregnant or breastfeeding 9. Secondary hypertension 10. Diastolic blood pressure outside 80 - 105 mmHg range after placebo run-in of six weeks 11. Not capable of giving informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin action will be measured by performing a hyperinsulinaemic, euglycaemic clamp, measured at the end of weeks 6, 18 and 36. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure will be measured using a standard automated blood pressure machine, measured at the end of weeks 2, 4, 6, 8, 12, 16, 18, 20, 22, 24, 26, 30, 34 and 36. | — |
Countries
United Kingdom
Outcome results
None listed